DE69924254D1 - Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks - Google Patents
Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucksInfo
- Publication number
- DE69924254D1 DE69924254D1 DE69924254T DE69924254T DE69924254D1 DE 69924254 D1 DE69924254 D1 DE 69924254D1 DE 69924254 T DE69924254 T DE 69924254T DE 69924254 T DE69924254 T DE 69924254T DE 69924254 D1 DE69924254 D1 DE 69924254D1
- Authority
- DE
- Germany
- Prior art keywords
- reminder
- medicament
- manufacture
- reducing eye
- adenosine antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9309798P | 1998-07-16 | 1998-07-16 | |
US12296599P | 1999-03-03 | 1999-03-03 | |
PCT/US1999/016211 WO2000003741A2 (en) | 1998-07-16 | 1999-07-15 | Methods for reducing intraocular pressure using a3-adenosine antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69924254D1 true DE69924254D1 (de) | 2005-04-21 |
Family
ID=26787065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69924254T Expired - Lifetime DE69924254D1 (de) | 1998-07-16 | 1999-07-15 | Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks |
Country Status (8)
Country | Link |
---|---|
US (2) | US6528516B1 (de) |
EP (1) | EP1096975B1 (de) |
JP (1) | JP2003522729A (de) |
AT (1) | ATE290910T1 (de) |
AU (1) | AU765423B2 (de) |
CA (1) | CA2337499A1 (de) |
DE (1) | DE69924254D1 (de) |
WO (1) | WO2000003741A2 (de) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6878716B1 (en) | 1998-06-02 | 2005-04-12 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptor and uses thereof |
US6686366B1 (en) | 1998-06-02 | 2004-02-03 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
IL139787A0 (en) | 1998-06-02 | 2002-02-10 | Osi Pharm Inc | PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE |
US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
ES2172415B2 (es) | 2000-07-28 | 2003-11-16 | Univ Madrid Complutense | Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina. |
US6897201B2 (en) | 2000-08-21 | 2005-05-24 | Inspire Pharmaceuticals, Inc. | Compositions and methods for the treatment of glaucoma or ocular hypertension |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
EP1364953A4 (de) * | 2001-02-05 | 2004-06-09 | Otsuka Pharma Co Ltd | Triazolochinazolin- und pyrazolotriazolopyrimidinderivate, medizinische zusammensetzungen, mittel mit adenosin-a3-rezeptoraffinität, mittel, die den augeninnendruck senken, zubereitungen zur prävention und behandlung von glaukom und verfahren zur senkung des augeninnendrucks" |
DK1450811T3 (da) | 2001-11-30 | 2010-02-15 | Osi Pharm Inc | Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf |
US8080554B2 (en) | 2001-12-12 | 2011-12-20 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation |
CN1620294A (zh) | 2001-12-20 | 2005-05-25 | Osi药物公司 | 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途 |
US7084128B2 (en) * | 2002-01-18 | 2006-08-01 | Inspire Pharmaceuticals, Inc. | Method for reducing intraocular pressure |
EP2076267A4 (de) * | 2006-10-06 | 2013-07-31 | Univ Pennsylvania | Effektive abgabe von kreuz-spezies a3-adenosin-rezeptor-antagonisten zur reduzierung des augeninnendrucks |
US8916570B2 (en) | 2008-03-31 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists and antagonists |
AU2009231978C1 (en) * | 2008-03-31 | 2014-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine derivatives as A3 adenosine receptor- selective agonists |
WO2010014921A2 (en) * | 2008-08-01 | 2010-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor antagonists and partial agonists |
US9181253B2 (en) | 2008-08-01 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists, partial agonists, and antagonists |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
EP2523669B1 (de) | 2010-01-11 | 2016-12-07 | Inotek Pharmaceuticals Corporation | Kombination, kit und verfahren zur reduzierung des augeninnendrucks |
AU2011230580A1 (en) | 2010-03-26 | 2012-10-11 | Inotek Pharmaceuticals Corporation | Method of reducing intraocular pressure in humans using N6 -cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof |
US9227979B2 (en) | 2012-01-25 | 2016-01-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fluorescent antagonists of the A3 adenosine receptor |
PL2807178T3 (pl) | 2012-01-26 | 2017-12-29 | Inotek Pharmaceuticals Corporation | Bezwodne polimorfy azotanu (2R,3S,4R,5R)-5-(6-(cyklopentyloamino)-9H-puryn-9-ylo)-3,4-dihydroksytetrahydrofuran-2-ylo)metylu i sposoby ich wytwarzania |
MX2015013234A (es) | 2013-03-15 | 2016-04-15 | Inotek Pharmaceuticals Corp | Formulaciones oftalmicas. |
ES2578363B1 (es) | 2015-01-22 | 2017-01-31 | Palobiofarma, S.L. | Moduladores de los receptores A3 de adenosina |
CN108463463A (zh) | 2016-01-14 | 2018-08-28 | 韩德株式会社 | 拮抗a3腺苷受体的化合物、其制备方法、及其医学用途 |
ES2676535B1 (es) | 2017-01-20 | 2019-04-29 | Palobiofarma Sl | Moduladores de los receptores a3 de adenosina |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0688973B2 (ja) * | 1987-03-12 | 1994-11-09 | 京都薬品工業株式会社 | 1,4−ジヒドロピリジン誘導体 |
US6066642A (en) * | 1996-01-29 | 2000-05-23 | The United States Of America As Represented By The Department Of Health And Human Services | Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists |
GB9716463D0 (en) * | 1997-08-04 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic agents |
-
1999
- 1999-07-15 EP EP99935665A patent/EP1096975B1/de not_active Expired - Lifetime
- 1999-07-15 WO PCT/US1999/016211 patent/WO2000003741A2/en active IP Right Grant
- 1999-07-15 AT AT99935665T patent/ATE290910T1/de not_active IP Right Cessation
- 1999-07-15 JP JP2000559875A patent/JP2003522729A/ja active Pending
- 1999-07-15 DE DE69924254T patent/DE69924254D1/de not_active Expired - Lifetime
- 1999-07-15 CA CA002337499A patent/CA2337499A1/en not_active Abandoned
- 1999-07-15 AU AU51096/99A patent/AU765423B2/en not_active Ceased
- 1999-07-15 US US09/743,744 patent/US6528516B1/en not_active Expired - Lifetime
-
2003
- 2003-02-25 US US10/374,003 patent/US20030153626A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2337499A1 (en) | 2000-01-27 |
ATE290910T1 (de) | 2005-04-15 |
EP1096975A2 (de) | 2001-05-09 |
US6528516B1 (en) | 2003-03-04 |
WO2000003741A2 (en) | 2000-01-27 |
EP1096975B1 (de) | 2005-03-16 |
US20030153626A1 (en) | 2003-08-14 |
AU765423B2 (en) | 2003-09-18 |
AU5109699A (en) | 2000-02-07 |
JP2003522729A (ja) | 2003-07-29 |
WO2000003741A3 (en) | 2000-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69924254D1 (de) | Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks | |
DE69926806D1 (de) | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren | |
DE69926919D1 (de) | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren | |
BR0310047A (pt) | Análogos de 8-azaprostaglandina como agentes para diminuição de pressão intra-ocular | |
MXPA02012712A (es) | N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas. | |
TW200700070A (en) | Enhanced bimatoprost ophthalmic solution | |
BRPI0408690A (pt) | composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto | |
BRPI0418245B8 (pt) | composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes | |
BR0116505A (pt) | Compostos ou um sal deste farmaceuticamente aceitável, composições farmacêuticas, método para tratar ou prevenir doenças ou distúrbios onde um antagonista de um receptor de orexina humano é requerido, e, processo para a fabricação de composições farmacêuticas para o tratamento de distúrbios associados com o papel da orexina, especialmente da obesidade e distúrbios do sono | |
NO960630L (no) | Heterocykler anvendelige som neurokinin antagonister | |
NO963731L (no) | Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister | |
BR0314353A (pt) | Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio | |
DE69903333D1 (de) | Crf rezeptor-antagonisten und darauf bezogene methoden | |
KR880012227A (ko) | 도파민 수용체 길항제의 신규사용법 | |
ATE359794T1 (de) | 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes | |
PT1129096E (pt) | Antagonistas de receptor de crf e metodos de tratamento relacionados com os mesmos | |
MX344556B (es) | Agonista de subtipo de receptor 5-ht1a. | |
BR0009225A (pt) | Uso de um antagonista de nmda de baixa afinidade,e, método para tratar ou prevenir a depressão emum mamìfero | |
BR0208405A (pt) | Compostos de diidropirimina substituìdos com ciano e seu uso para tratar doenças | |
ZA202307013B (en) | Salt form of isoquinolinone type compound as rock inhibitor and preparation method therefor | |
BR0307627A (pt) | Métodos e composições para o tratamento de doenças do olho | |
PL360492A1 (en) | Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates | |
WO2002102978A3 (en) | Human growth hormone antagonists | |
BRPI0512525A (pt) | canabidióis anormais como agentes para diminuir a pressão intraocular e fornecer efeito neuroprotetor ao olho | |
ATE369856T1 (de) | Verfahren zur behandlung von glaukom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de |